Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1999-11-08
2000-10-03
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514258, A61K 31505
Patent
active
061273708
ABSTRACT:
A method is provided for treating occlusive vascular disease or Alzheimer's disease, wherein the patient has at least moderately elevated blood levels of homocysteine and at least moderately reduced blood levels of folate and vitamin B.sub.12, wherein the patient is treated with folic acid, a folate or a derivative thereof, and optionally vitamin B.sub.12, and optionally an organic nitrate such as isosorbide mononitrate or dinitrate, or an ACE inhibitor or an angiotensin II antagonist, or a NEP/ACE inhibitor or a combination of two or more of the above.
REFERENCES:
McCully, K.S., "Homocysteine and vascular disease", Mature Med., 1996; 2:386-389.
Blundell, G. et al., "Homocysteine mediated endothelial cell toxicity and its amelioration", Atherosclerosis, 1996; 122:163-172.
Stamler, J.S. et al, "Biological Chemistry of Thiols in the Vasculature and in Vascular-related Disease", Nutr. Rev., 1996; 54:1-30.
Brattstrom, L.E. et al, "Moderate Homocysteinemia--A Possible Risk Factor For Arteriosclerotic Cerebrovascular Disease", Stroke, 1984; 15:1012-6.
Brattstrom, L. et al, "Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors", Eur. J. Clin. Invest., 1992; 22:214-221.
Boushey, C.J. et al, "A quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease", J. Am. Med. Assoc., 1995; 274:1049-1057.
Ubbink, J.B. et al, "Vitamin Requirements for the Treatment of Hyperhomocysteinemia in Humans", J. Nutr., 124:1927-1933.
Wulfert, E., "Treatament Development Strategies for Alzheimer's Disease", European J. Medicinal Chemistry 30(Suppl): 148s-162s.
Young, J.B., "Angiotensin-Converting Enzyme Inhibitors Post-Myocardial Infarction", Cardiology Clinics, vol. 13, No. 3, Aug. 1995, pp. 379-390.
Frosst, P., et al, "A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase", Nature Genetics, vol. 10, May 1995, pp. 111-113.
Barnes, N.M., et al, "Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease", Europ. J. of Pharmacology, 200(1991) 289-292.
Lansbury, P.T., Jr., "Consequences of the Molecular Mechanism of Amyloid Formation for the Understanding of the Pathogenesis of Alzheimer's Disease and the Development of Therapeutic Strategies", Arzneimittel-Forschung, 1995, 45(3A): 452-434.
Takeda, H., et al, "Protective Effect of the Angiotensin-Converting Enzyme Inhibitor Captopril on Postischemic Myocardial Damage in Perfused Rat Heart", Jpn. Circ. J., 1997; 61:687-694.
Ishibashi, Y., et al, "The Nitric Oxide Donor ITF 1129 Augments Subendocardial Blood Flow During Exercise-Induced Myocardial Ischemia", J. of Cardiovascular Pharmacology, vol. 30, No. 3, pp. 374-382.
Piana, R.N., et al, "Angiotensin-Converting Enzyme Inhibition Preserves Endothelium-Dependent Coronary Microvascular Responses During Short-term Ischemia-Reperfusion", Circulation, 1996, vol. 93, No. 3, pp. 544-551.
Munzel, T., et al, "Long-term Angiotensin-Converting Enzyme Inhibition With High-Dose Enalapril Retards Nitrate Tolerance in Large Epicardial Arteries and Prevents Rebound Coronary Vasoconstrictin In Vivo", Circulation, 1996; 93:2052-2058.
Birincioglu, M., et al, "Protective Effect of ACE Inhibitors on Ischemia-Reperfusion-induced Arrhythmias in Rats: Is this Effect Related to the Free Radical Scavenging Action of these Drugs?", Free Rad. Res. vo. 27(4) pp. 389-396 (1997).
Ii, Kunio, "The Role of .beta.-Amyloid in the Development of Alzheimer's Disease", Drugs & Aging 7(2):97-109, (1995).
Plosker, G.L., et al, "Captopril A Review of its Pharmacology and Therapeutic Efficacy After Myocardial Infarction and in Ischaemic Heart Disease", Drugs & Aging 7(3); 226-253 (1995).
Buee, L. et al, "Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders", Acta Neuropathol (1994) 84:469-480.
Boushey, C.J. et al, "A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease", J. Am. Med. Assoc. 1995, vol. 274, 1049-1057.
Nygard, O. et al, "Total Plasma Homocysteine and Cardiovascular Risk Profile", J. Am. Med. Assoc., 1995, vol. 274, 1526-1533.
Riggs, K.M. et al, "Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study", Am. J. Clin. Nutr., 1996;63:306-314.
Renvall, M.J. et al, "Nutritional Status of Free-Living Alzheimer's Patients", Am. J. Med. Sci, 1989;298:20-27.
Cole, M.G. et al, "Low Serum Vitamin B.sub.12 in Alzheimer-Type Dementia", Age Ageing, 1984, 13:101-105.
Karnaze, D.S. et al, "Low Serum Cobalamin Levels in Primary Degenerative Dementia", Arch. Intern. Med., 1987;147:429-431.
Nijst, T.Q. et al, "Vitamin B12 and folate concentrations in serum and cerebrospinal fluid of neurological patients with special reference to multiple sclerosis and dementia", J. Neurol. Neurosurg. Psychiatry, 1990; 53:951-954.
Beal, M.F. et al, "Neurochemical Characterization of Excitotoxin Lesions in the Cerebral Cortex", J. Neurosci., 1991; 11:147-158.
Bottiglieri, T. et al, "The Clinical Potential of Ademetionine (S-Adenosyl-methionine) in Neurological Disorders", Drugs, 1994; 48:137-152.
Bird, A.P., "Functions for DNA Methylation in Vertebrates", Cold Spring Harb Symp Quant Biol, 1993; 58:281-285.
Mullaart, E. et al, "Increased Levels of DNA Breaks in Cerebral Cortex of Alzheimer's Disease Patients", Neurobiol Aging, 1990; 11:169-173.
Clark, R.F. et al, "The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families", Nat. Genet, 1995; 11:219-222.
Stampfer, M.J. et al, "Folate and Cardiovascular Disease: Why We Need a Trial Now", J. Am. Med. Assoc., 1996; 275:1929-1930.
Rolland, P.H. et al, "Hyperhomocysteinemia-Induced Vascular Damage in the Minipig. Captopril-Hydrochlorthiazide Combination Prevents Elastic Alterations", Circulation, 1995; 91:1161-1174.
Jobst Kim Anthony
Smith Anthony David
Bristol--Myers Squibb Company
Criares Theodore J.
Rodney Burton
LandOfFree
Method for treating alzheimer's disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating alzheimer's disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating alzheimer's disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-195814